BioSpace News Archive

Transparency Market Research has published a new report titled, ‘Topical Pain Management Therapeutics in Sports Medicine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

The global respiratory syncytial virus therapeutics market was valued at approximately US$ 820.0 Mn in 2016 is projected to expand at a CAGR of more than 11.0% from 2017 to 2025, according to a new report published by Transparency Market Research titled “Respiratory Syncytial Virus Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.

The global neuroprotection market was valued at approximately US$ 47,000.0 Mn in 2016 is projected to register a growth rate of 8.2% from 2017 to 2025, according to a new report published by Transparency Market Research titled “Neuroprotection Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.

The prevalence of rare diseases has surged in recent years, as the tracking of their incidence has improved around the world in the past few decades.

The global Guillain–Barré syndrome market was valued at US$ 454.0 Mn in 2016 and is expected to expand at a high CAGR of 5% from 2017 to 2025, to reach value of US$ 708.6 Mn by 2025, according to a new report published by Transparency Market Research titled “Guillain–Barré Syndrome Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025.”

ANGLE plc, a world-leading liquid biopsy company, announces that its Annual General Meeting will be held at 2:00 pm on Thursday 27 August 2020 as a closed meeting at ANGLE plc, 10 Nugent Road, Surrey Research Park, Guildford, GU2 7AF.

Evotec SE and the leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG, announced a strategic partnership in the field of antisense oligonucleotide -based therapeutics.

Comprehensive long-term platform agreement for the development of novel antisense oligonucleotide therapeutics across a broad range of targets and indications

MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, announced the successful completion of its first clinical trial of anle138b in healthy volunteers.

Marken announced the opening of their purpose-built cell and gene control center in North Carolina, USA.